VENT-03 not checked
Ventus Therapeutics U.S., Inc.
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus), CLE
- Main trialPhase 2
- “The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to answer are: * Does VENT-03 affect the activity and severity of CLE? * What side effects do participants have when taking VENT-03? Researchers will compare VENT-03 to a placebo (a look-alike substance that contains no drug) to see if VENT-03 works to treat patients with CLE. Participants will: *…”In the company’s words, NCT07260877 on ClinicalTrials.gov
Other drugs for Cutaneous Lupus Erythematosus (CLE)
- EnpatoranEMD Serono Research & Development Institute, Inc. · Phase 3
- LitifilimabBiogen · Phase 3
- AfimetoranBeeline Medicines Corporation · Bristol Myers Squibb · Phase 2/3
- AnifrolumabAstraZeneca · Phase 3
- ICP-488Beijing InnoCare Pharma Tech Co., Ltd. · Phase 2
- DB-2304DualityBio Inc. · Phase 1/2
Coming up1
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Dec 2026 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026